•
AB
ABBV
ABBVIE INC.
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
378.29B
Volume
10.73M
52W High
$244.81
52W Low
$164.39
Open
$212.47
Prev Close
$214.04
Day Range
211.57 - 218.00
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Latest News
Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative
Investing.com•16h ago
Bioconjugation Market Size to Hit USD 14.51 Billion by 2033, Driven by the Increasing Demand for Targeted Therapeutics – SNS Insider
GlobeNewswire Inc.•Jan 19
Could Buying This Stock Today Pay Off Big Over the Next 5 Years?
The Motley Fool•Jan 18
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
GlobeNewswire Inc.•Jan 16
Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends
GlobeNewswire Inc.•Jan 16
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight
GlobeNewswire Inc.•Jan 13
AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines
Benzinga•Jan 13
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
Benzinga•Jan 9